OPERATE. DEVELOP. COMPOUND.
Entering a market is not the same as developing one.
A company can open conversations, appoint a partner, win an early opportunity or complete a market-entry test — and still lack the continuity required to build a durable commercial position.
MD12 is a 12-month Externalized Business Development function designed for companies that need sustained market-facing capacity, account development, opportunity progression, governance and commercial continuity.
The mandate is not built around a one-off launch. It is built around maintaining disciplined commercial movement over time.
WHEN THE QUESTION CHANGES
ME90 asks:
Does this market deserve continued investment — and what should happen next?
MD12 asks:
How do we maintain, deepen and compound market development over time?
The problem is different.
Once a market deserves continued attention, leadership must manage:
MD12 exists to operate that continuity.
WHO MD12 IS FOR
MD12 may follow ME90, but it does not require ME90 where sufficient market clarity already exists.
A 12-MONTH OPERATING RHYTHM
Months 01–03
Build the commercial operating baseline.
Typical work:
Primary output:
Market Development Baseline
Create a disciplined operating base for sustained development.
Months 04–06
Progress accounts and shape opportunities.
Typical work:
Primary output:
Account / Opportunity Development Review
Move from presence to controlled account and opportunity development.
Months 07–09
Build depth around the strongest commercial signals.
Typical work:
Primary output:
Pipeline + Relationship Expansion Review
Build greater depth where the market is showing credible potential.
Months 10–12
Turn accumulated learning into the next operating cycle.
Typical work:
Primary output:
Annual Review + Next-Cycle Recommendation
Ensure that a year of market activity becomes institutional learning and a better next decision.
MD12 IS AN OPERATING FUNCTION, NOT A CAMPAIGN
MD12 is designed to prevent that fragmentation.
VIAPORA maintains the commercial thread across accounts, opportunities, evidence, blockers and decisions.
The objective is not constant activity. It is consistent progression.
HOW VIAPORA TREATS THE DOSSIER OVER TIME
Structured internal systems may support the organization of information, evidence, follow-up, account movement and decision inputs. But material qualification, interpretation, prioritisation, escalation and commercial recommendations remain subject to senior human review.
Structured systems support continuity.
Senior judgement protects context and accountability.
VIAPORA continuously asks:
The dossier evolves as the market evolves.
WHAT VIAPORA OPERATES
Account strategy, Decision-maker access, Senior outreach, Qualification, Relationship development, Structured follow-up, Opportunity progression, Next-action discipline, Partner or stakeholder development where relevant, Evidence capture, Blocker management, Operating reviews, Market-development recommendations
The exact mandate is defined by market, ICP, responsibilities, deliverables, exclusions, cadence and review gates.
WHAT THE CLIENT RETAINS
MD12 can maintain market continuity.
It cannot compensate indefinitely for unresolved client-side decisions.
The client remains the authority on:
The client must also provide timely access to:
GOVERNANCE WITHOUT REPORTING THEATRE
A disciplined operating rhythm should make visible:
Reporting documents execution. It does not replace execution.
WHAT LEADERSHIP SHOULD BE ABLE TO SEE
The purpose is not to create a larger CRM. It is to create better commercial control.
MD12 IS NOT
Sustained market development requires continuity, but continuity must remain accountable.
ME90 may lead to MD12 when evidence justifies continued development.
MD12 may also begin directly where the market hypothesis is already sufficiently established.
The mandate should always match the market's actual maturity.